Pacira Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam.The company was founded in December 2006 and is headquartered in Tampa, FL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Pacira Pharmaceuticals reports record revenues and optimistic growth outlook

Pacira Pharmaceuticals had a strong financial performance in 2022, driven by EXPAREL's success and strategic initiatives. While facing challenges in pricing and reimbursement, the company is optimistic about future opportunities for growth through label expansions and market strategies.

Pacira Pharmaceuticals (PCRX) excels in Q1 2023 earnings call

Pacira Pharmaceuticals (PCRX) demonstrated robust financial performance, innovation in non-opioid pain management, and strategic market positioning in Q1 2023.
While facing challenges such as potential surgery trend moderation and pediatric market penetration, the company is leveraging opportunities in expanding EXPAREL use and regulatory advancements.
Overall, Pacira's focus on patient-centric solutions and market expansion initiatives position it well for continued growth and leadership in the pain management sector.

Pacira Pharmaceuticals reports strong Q2 performance and eyes growth

Pacira Pharmaceuticals delivered a strong Q2 performance with robust revenues, led by EXPAREL sales and improved gross margins, showcasing financial stability and growth potential.
While facing challenges in market adoption and regulatory hurdles, the company's strategic strengths in non-opioid pain management and product diversification present opportunities for long-term growth.
Anticipated initiatives like the NOPAIN Act and the launch of a lower extremity nerve block offer significant growth prospects, positioning Pacira Pharmaceuticals for continued success in the market.
Overall, Pacira Pharmaceuticals' focus on innovation, market access, and operational efficiency underscores its commitment to sustainable growth and leadership in non-opioid pain management.

Pacira Pharmaceuticals adjusts EXPAREL sales guidance amidst growth opportunities

Pacira Pharmaceuticals (PCRX) navigated market challenges by adjusting EXPAREL sales guidance while maintaining financial targets. Strong performance in EXPAREL and other product lines, coupled with strategic investments and partnerships, position the company for future growth. Addressing competitive threats and seizing expansion opportunities are key focus areas for sustained success.

Pacira Pharmaceuticals reports robust Q4 performance and strategic growth plans

Pacira Pharmaceuticals (PCRX) showcases strong financial performance and strategic focus on non-opioid pain management.
Challenges include patent defense against eVenus and organizational restructuring for sustainable growth.
Opportunities lie in EXPAREL's growth trajectory, NOPAIN legislation, and expanding therapeutic strategies.
Overall, Pacira Pharmaceuticals is poised for continued success amid the opioid crisis, with a clear vision for future growth.

Pacira Pharmaceuticals sees growth potential with EXPAREL and gene therapy

Pacira Pharmaceuticals reports strong sales performance for EXPAREL and other products, despite margin impacts.
The company is focused on growth and penetration in the marketplace, leveraging new indications and partnerships.
PCRX-201 shows promise for future growth opportunities, supported by FDA's RMAT designation.
Analyst questions and challenges like maintaining margins and capital allocation decisions are areas of focus for Pacira.

Pacira Pharmaceuticals excels in Q2 2024, poised for strategic growth

Pacira Pharmaceuticals (PCRX) demonstrated strong performance and strategic focus in Q2 2024, with notable achievements in product development and financial stability.
While facing challenges such as patent litigation and competitive pressures, Pacira's strengths in execution and market positioning provide a solid foundation for growth.
The company's clear guidance for 2024 and emphasis on growth priorities underscore its commitment to innovation and market leadership.
By capitalizing on opportunities in product expansion, market dynamics, and strategic partnerships, Pacira is poised for continued success and growth in the healthcare sector.

Pacira Pharmaceuticals (PCRX) reports robust Q3 performance and eyes gene therapy growth

Pacira Pharmaceuticals (PCRX) delivered a strong performance in Q3 2024, driven by increased EXPAREL sales and strategic initiatives. While facing challenges in legal battles and operational areas, the company remains focused on growth opportunities and maintaining a competitive edge in the market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Pacira Biosciences, Inc. is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Pacira (PCRX) is a Top-Ranked Momentum Stock: Should You Buy?

TAMPA, Fla., March 09, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Barclays Global Healthcare Conference at 10:15 AM ET on Wednesday, March 16, 2022 in Miami. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Participate in Fireside Chat at the Barclays Global Healthcare Conference

Pacira's (PCRX) flagship product, Exparel, has been performing well since its launch. The company's efforts to expand the drug's label also holds promise.

Pacira (PCRX) Rides High in YTD Period on Robust Exparel Sales

Pacira's (PCRX) earnings surpass estimates in the fourth quarter of 2021 while revenues are slightly above estimates.

Pacira's (PCRX) Q4 Earnings Beat Estimates, Revenues Rise Y/Y

Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q4 2021 Results - Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of 16.87% and 0.27%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Q4 Earnings and Revenues Beat Estimates

— Anesthesia-driven regional approaches drive record EXPAREL sales of $507 million in 2021 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $204 million — — More than 10 million patients have received EXPAREL since launch — — Conference call today at 8:30 a.m. ET —

Pacira BioSciences Reports Full-Year and Fourth Quarter 2021 Financial Results

Pacira (PCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Pacira (PCRX) Q4 Earnings Expected to Decline

TAMPA, Fla., Feb. 16, 2022 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX) today announced that it will report its fourth quarter and year ended December 31, 2021 financial results before the open of the U.S. markets on Thursday, February 24, 2022. Following the release, the company will host a live conference call and webcast at 8:30 a.m. ET.

Pacira to Report 2021 Financial Results on Thursday February 24, 2022

-- EXPAREL average daily sales for January 2022 were 104% of January 2021 -- -- EXPAREL average daily sales for January 2022 were 104% of January 2021 --

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL and iovera° of $37.3 Million for January 2022

Pacira (PCRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Will Pacira (PCRX) Beat Estimates Again in Its Next Earnings Report?

ArcBest

Axis Capital

CF Industries Holdings

D.R. Horton

PCRX, DHI, ARCB, AXS and CF balance value and growth and are therefore worth picking up.

5 Reasons to Bet On These 5 Buy Ranked Stocks

Pacira (PCRX) could produce exceptional returns because of its solid growth attributes.

Pacira (PCRX) is an Incredible Growth Stock: 3 Reasons Why

The company reports an EPS beat of $0.72 in the third quarter. We look into how management has been employing its capital.

Pacira BioSciences: Higher Prices On The Horizon

-- Provides additional operational and financial flexibility -- -- Underscores strength of forecasted earnings and operating cash flow --

Pacira BioSciences Announces Closing of $375 Million Five-Year Term Loan B

-- EXPAREL average daily sales for November 2021 - 122% of November 2020 –

Pacira BioSciences Reports Preliminary Net Product Sales for EXPAREL® and iovera° of $48.0 Million for November 2021

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock?

Pacira (PCRX) Down 4.5% Since Last Earnings Report: Can It Rebound?

TAMPA, Fla., Nov. 23, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX) today announced that it will participate in an analyst-led fireside chat at the Piper Sandler 33rd Annual Virtual Healthcare Conference at 9:30 AM ET on Tuesday, November 30, 2021. Live audio of the event can be accessed by visiting the “Events” page of the company's website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.

Pacira BioSciences to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference

-- Adds highly complementary ZILRETTA ® to Pacira commercial offering -- -- Combined portfolio offers end-to-end non-opioid solutions along the pain pathway --

Pacira BioSciences Completes Acquisition of Flexion Therapeutics and Strengthens Leadership Position in Non-Opioid Pain Management

EXPAREL average daily sales for October 2021 were 109% of October 2020 EXPAREL average daily sales for October 2021 were 109% of October 2020

Pacira BioSciences Reports Preliminary Net Product Sales of $44.3 Million for October 2021

TAMPA, Fla., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced that it has filed a lawsuit in the United States District Court for the District of New Jersey against eVenus Pharmaceutical Laboratories, Inc. for patent infringement of U.S. Patent Number 11,033,495. The '495 patent is related to EXPAREL® (bupivacaine liposome injectable suspension) and has an expiration date of January 22, 2041. The complaint is seeking an injunction to prevent the infringing manufacture, use, and sale of a potential generic product described in an Abbreviated New Drug Application (ANDA) that eVenus filed with the U.S. Food and Drug Administration in August 2021. The filing of the lawsuit triggered a 30-month stay of final approval of eVenus' ANDA under the Hatch Waxman Act.

Pacira Files Lawsuit Against eVenus for Patent Infringement

Pacira's (PCRX) earnings beat estimates in the third quarter of 2021 while revenues miss the same. Its flagship product Exparel's sales rise year over year.

Pacira's (PCRX) Q3 Earnings Beat Estimates, Revenues Miss Mark

Pacira BioSciences, Inc. (PCRX) CEO Dave Stack on Q3 2021 Results - Earnings Call Transcript

Pacira (PCRX) delivered earnings and revenue surprises of 9.09% and -2.11%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Pacira (PCRX) Beats Q3 Earnings Estimates

-- Third quarter GAAP net income of $17.7 million and adjusted EBITDA of $48.1 million -- -- Conference call today at 8:30 a.m. ET --

News for Pacira Pharmaceuticals Stock (PCRX)